Table 4: Comparison of NHL rates between different regions and Europe:
Crude and adjusted HRs for being diagnosed with NHL at 2 years after ART start in different population groups.
| Women1 | All men1 | Heterosexual men2 | MSM2 | |||||
|---|---|---|---|---|---|---|---|---|
| Crude HR (95% CI) | Adjusted HR* (95% CI) | Crude HR (95% CI) | Adjusted HR* (95% CI) | Crude HR (95% CI) | Adjusted HR** (95% CI) | Crude HR (95% CI) | Adjusted HR** (95% CI) | |
| Region | ||||||||
| Europe | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| North America | 1.66 (1.14 – 2.41) | 0.97 (0.64 – 1.49) | 1.74 (1.45 – 2.08) | 1.10 (0.85–1.43) | 1.74 (1.26–2.40) | 1.26 (0.92–1.74) | 1.72 (1.38–2.14) | 1.20 (0.96–1.49) |
| Latin America | 0.36 (0.13 – 0.98) | 0.26 (0.09 – 0.77) | 0.84 (0.59 – 1.22) | 0.64 (0.38 – 1.09) | 0.80 (0.45–1.43) | 0.72 (0.41–1.27) | 1.03 (0.68–1.57) | 0.84 (0.55–1.27) |
| South Africa | 1.48 (1.03 – 2.14) | 1.79 (1.19 – 2.70) | 0.80 (0.51 – 1.25) | 0.94 (0.56 – 1.58) | − | − | − | − |
1
From models including the variable “sex” and its interaction with region.
2
From models including the variable “exposure group” and its interaction with region.
*
Adjusted for age at ART start, calendar period of ART start, first-line ART regimen, current CD4 cell count and its interaction with region, and sex and its interaction with region (model 1).
**
Adjusted for age at ART start, calendar period of ART start, first-line ART regimen, current CD4 cell count, drug use, and exposure group and its interaction with region (model 3).
ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio; NHL, non-Hodgkin lymphoma.